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1. Introduction
Wound healing is a complex dynamic biological process which has four partly overlapping
phases: hemostasis, inflammation, proliferation and remodeling. These phases involve a large
number of cell types, extracellular components, growth factors and cytokines. [1]
The extracellular matrix (ECM) of mammalian tissues has been used as a scaffold to facilitate
the repair and reconstruction of numerous tissues. Such scaffolds are prepared in many forms
including sheets, powders, and hydrogels. [2]
The ECM is a complex network structure that surrounds and supports cells. It is filled with
ECM molecules like proteins and proteoglycans, which are secreted by the cells. Cell receptors
bind both soluble and tethered signaling cues from the ECM environment, while simultane‐
ously, cells send out signals to actively construct and degrade their microenvironment for
remodeling. Thus, the ECM acts not only as a mechanical scaffold for the cells, but also a
bioactive and dynamic environment that mediates cellular functions. [3,4,5]
It is highly desirable to synthesize scaffolds to mimic the structure and biofunctions of the
natural ECM. [3,6,7,8]
2. ECM-like scaffolds
A widely-cited challenge in the field of tissue engineering is to provide a blood vessel network
to facilitate oxygen, nutrient, biochemical and waste exchange for thick tissues beyond the
range of diffusion. In the absence of a blood vessel network, necrosis will quickly occur beyond
the surface of any implanted, metabolic tissue. [9,10]
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Extracellular matrix (ECM) proteins, such as fibronectin, laminin and collagen IV, play
important roles in many cellular behaviors, including cell adhesion and spreading. Under‐
standing their adsorption behavior on surfaces with different natures is helpful for studying
the cellular responses to environments. [11]
Various polymers, including natural, synthetic and natural/synthetic hybrid polymers, have
been used to make hydrogels via chemical or physical crosslinking. Recently, bioactive
synthetic hydrogels have emerged as promising scaffolds because they can provide molecu‐
larly tailored biofunctions and adjustable mechanical properties, as well as an extracellular
matrix-like microenvironment for cell growth and tissue formation. [3]
Glycosaminoglycans (GAGs) are ubiquitously present at the cell surface and in extracellular
matrix, and crucial for matrix assembly, cell-cell and cell-matrix interactions. The supramo‐
lecular presentation of GAG chains, along with other matrix components, is likely to be
functionally important but remains challenging to control and to characterize, both in vivo
and in vitro. [12] The ECM component hyaluronic acid (HA) possesses a non-sulfated glyco‐
saminoglycan (GAG) structure and is widely distributed throughout the ECM of all connective
tissues. HA plays an essential role in many biological processes such as tissue hydration,
nutrient diffusion, proteoglycan organization and cell differentiation.
Various proteins have been used to make natural-hydrogel tissue-engineering scaffolds.
Among them, collagen, the most abundant protein in mammals, is a representative natural
polymer to fabricate natural hydrogels. Collagen can be degraded naturally by metallomatrix
proteinases (MMPs) – specifically, collagenase – allowing for local degradation controlled by
cells present in the engineered tissue. [3]
2.1. Injectable hydrogels
Injectable hydrogels derived from the extracellular matrix (ECM) of decellularized tissues have
recently emerged as scaffolds for tissue-engineering applications. [13]
ECM hydrogels provide advantages such as injectability, the ability to fill an irregularly shaped
space, and the inherent bioactivity of native matrix. However, material properties of ECM
hydrogels and the effect of these properties upon cell behavior are neither well understood
nor controlled. [2] The objective of the study, made by Wolf et al. was to prepare and determine
the structure, mechanics, and the cell response in vitro and in vivo of ECM hydrogels prepared
from decellularized porcine dermis and urinary bladder tissues. Dermal ECM hydrogels were
characterized by a more dense fiber architecture and greater mechanical integrity than urinary
bladder ECM hydrogels, and showed a dose dependent increase in mechanical properties with
ECM concentration. In vitro, dermal ECM hydrogels supported greater C2C12 myoblast
fusion, and less fibroblast infiltration and less fibroblast mediated hydrogel contraction than
urinary bladder ECM hydrogels. Both hydrogels were rapidly infiltrated by host cells,
primarily macrophages, when implanted in a rat abdominal wall defect. Both ECM hydrogels
degraded by 35 days in vivo, but UBM hydrogels degraded more quickly, and with greater
amounts of myogenesis than dermal ECM. These results show that ECM hydrogel properties
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can be varied and partially controlled by the scaffold tissue source, and that these properties
can markedly affect cell behavior. [2]
Seif-Naraghi et al. introduce the potential for using a decellularized ECM-derived hydrogel
for the improved delivery of heparin-binding growth factors. Immobilization of growth factors
on a scaffold has been shown to increase their stability and activity. This can be done via
chemical crosslinking, covalent bonding, or by incorporating natural or synthetic growth
factor-binding domains similar to those found in vivo in sulfated glycosaminoglycans (GAGs).
Many decellularized ECM-derived hydrogels retain native sulfated GAGs, and these materials
may therefore provide an excellent delivery platform for heparin-binding growth factors. In
his study, the sulfated GAG content of an ECM hydrogel derived from decellularized peri‐
cardial ECM was confirmed by Fourier transform infrared spectroscopy and its ability to bind
basic fibroblast growth factor (bFGF) was established. Delivery in the pericardial matrix
hydrogel increased retention of bFGF both in vitro and in vivo in ischemic myocardium
compared to delivery in collagen. In a rodent infarct model, intramyocardial injection of bFGF
in pericardial matrix enhanced neovascularization by approximately 112% compared to
delivery in collagen. Importantly, the newly formed vasculature was anastomosed with
existing vasculature. Thus, the sulfated GAG content of the decellularized ECM hydrogel
provides a platform for incorporation of heparin-binding growth factors for prolonged
retention and delivery. [13]
2.2. Acellular flowable matrix
In recent years development of new technologies and therapies aimed to treat hard-to-heal
wounds. The formation of a sinus tract complicates these difficult-to-treat diabetic wounds
even further. In the lower extremity, sinus tract wounds are a significant risk for osteomyelitis.
Typical treatment includes extensive surgical debridement with radical dissection, cavity
packing, and occlusive dressing. Cellular and acellular bioengineered grafts have demonstrat‐
ed some promise as alternatives for the treatment of such wounds. [14,15,16,17]
However, these grafts are provided as sheets in planar form. As such, they are harder to use
and less effective in sinus tract wounds because of the irregularly shaped tunnels or extensions
in these wounds. Ideally, the matrix material is capable of conforming to the wound area and
providing the necessary bulk and scaffold to support the woundhealing process. [17]
An injectable form of an acellular human dermal regenerative tissue matrix Graftjacket®
Xpress Flowable Soft Tissue Scaffold was designed to treat difficult tunneling wounds in a
minimally invasive manner. This injectable matrix is a micronized form of a human acellular
dermal regenerative tissue matrix. The injectable human matrix is composed of a micronized
or powdered version of the graftjacket membrane. The matrix membrane is a human acellular
scaffold derived from human dermal tissue. It is biocompatible and biologically permissive.
This dermal matrix retains its native extracellular matrix proteins such as collagens I, III, IV,
and VII; elastin; and proteoglycans in cell-friendly forms.
Although the sheet form of the scaffold does demonstrate intact vascular channels that allows
for rapid angiogenesis, those channels are destroyed in the micronization process. The
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flowable matrix allows for nutritional diffusion and cell attachment to facilitate cell migration
as well as proliferation. These properties result in the rapid revascularization and cellular
repopulation of the matrix scaffold. [17]
Graftjacket® Xpress FSTS supports the body's repair of damaged or inadequate integumental
tissue, such as deep dermal wounds or diabetic ulcers. Graftjacket® FSTS is supplied as a dried,
acellular dermal particulate in a syringe, before aplication it is reconstituted through syringe
adapter with sterile saline solution and applied directly into the debrided, clean wound
through a flexible applicator tip. The product is recomended for burns, chronic wounds as
diabetic foot ulcers, pressure ulcers, surgical wounds ans venous ulcers.
Another interesting commercially available product is Integra® Flowable Wound Matrix. It is
an advanced wound care device comprised of a granulated Integra® Wound Matrix, which
consists of collagen and glycosaminoglycan. Collagen is of bovine origin. The Integra®
Flowable Wound Matrix is hydrated with saline prior to application. It is designed for use in
deep soft tissue or tunneling wounds. Gel-like consistency allows intimate contact between
the grafting material and wound bed, composition and method of administration allows for
complete coverage in deep crevice wounds. It provides a resorbable scaffold on which cells
can attach, migrate, proliferate and differentiate.
Integra® Flowable Wound Matrix is indicated for the management of wounds including:
partial-and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic
vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-laser
surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree
burns, skin tears) and draining wounds.
3. Review of recent clinical experience with acellular matrix
Schmidt et al. in his retrospectively study concluded, that acellular porcine dermal collagen
matrix is a feasible and reliable biological patch material for reconstruction of the thoracic wall.
Excellent wound healing and long-term stability were achieved even in large defects or
complete sternal replacements. Biological collagen matrixes have emerged as an alternative to
the routinely used synthetic materials by major thoracic wall resections. Histological exami‐
nation showed integration, neovascularization, and long-term persistence of the collagen
matrix on late reoperation of one patient. [18]
The results of the multicenter prospective study from Kavros et al. demonstrate that the use
of fetal bovine acellular dermal matrix (PriMatrix) integrated with standard-of-care therapy is
a successful treatment regimen to heal diabetic foot ulcers (DFUs). In the study were included
patiets with chronic DFU that ranged in area from 1 to 20 cm and failed to heal more than 30%
during a 2-week screening period when treated with moist wound therapy. For qualifying
subjects, PriMatrix was secured into a clean, sharply debrided wound; dressings were applied
to maintain a moist wound environment, and the DFU was pressure off-loaded. Wound area
measurements were taken weekly for up to 12 weeks, and PriMatrix was reapplied at the
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discretion of the treating physician. 55 patiets were enrolled at 9 US centers with 46 subjects
progressing to study completion. Ulcers had been in existence for an average of 286 days, and
initial mean ulcer area was 4.34 cm. Of the subjects completing the study, 76% healed by 12
weeks with a mean time to healing of 53.1 ± 21.9 days. The mean number of applications for
these healed wounds was 2.0 ± 1.4, with 59.1% healing with a single application of PriMatrix
and 22.9% healing with 2 applications. For subjects not healed by 12 weeks, the average wound
area reduction was 71.4%. [19]
Goyal et al. evaluate in the study the degree of patient acceptance with acellular dermal matrix
(ADM) allograft in the treatment of buccal gingival recession and compare it with subepithelial
connective tissue graft. Obtaining predictable and aesthetic root coverage has become an
important part of periodontal therapy. The search for the appropriate root coverage techniques
has resulted in many different approaches. In the study thirty patients with Miller's class II
recessions were treated and randomly assigned to the test group (ADM) and control group
(subepithelial connective tissue graft). All patients underwent full periodontal evaluation and
pre-surgical preparation, including oral hygiene instructions and scaling and root planing. The
exposed roots were thoroughly planed and covered by a graft without any further root
treatment. Results were evaluated based on the parameters measuring patient satisfaction and
clinical outcome after 6 months of the surgical procedure. Postoperatively, significant root
coverage, reduction in probing depth, gain in clinical attachment level, and increase in widths
of keratinized tissue and attached gingiva were observed on intra-group comparison. There
was no significant difference in any of the parameters between test and control groups. The
subepithelial connective tissue graft and ADM graft were able to successfully treat gingival
recession defects; however, the ADM showed better patient acceptance than the connective
tissue graft. [20]
Wang et al. made an interesting prospective randomized multi-center study with comparison
of two differently processed acellular dermal matrix products for root coverage procedures.
They have compared 2 acellular dermal matrix (ADM) materials produced by different
processing techniques, freeze-dried (FDADM) and solvent-dehydrated ADM (SDADM), in
their ability to correct Miller's Class I and II recession defects. Eighty subjects from four study
centers, each with a single maxillary anterior Miller's class I or II recession defect were enrolled.
Subjects were randomly assigned and treated with coronally advanced flap (CAF)+FDADM
(N=42) or CAF+SDADM (N=38). Gingival thickness, recession depth, recession width, probing
pocket depth, clinical attachment level, Gingival index, Plaque index, patient discomfort and
wound healing index were recorded before surgery, immediately post surgery, and over 2, 4,
12, 24 and 52 weeks postoperatively. When evaluating the clinical parameters after one year,
both groups showed significant (P<0.05) improvement for most of the parameters evaluated
when compared to baseline (Day 0). For example, percentage of root coverage was 77.20% ±
29.10% for CAF+FDADM and 71.01% ± 32.87% for CAF+SDADM. On the other hand, no
significant differences were observed between the two materials for any clinical parameter
tested or for patient satisfaction except for PD on the mesial side of the defects (p=0.03). As a
conclusion both ADM materials, freeze-dried or solvent-dehydrated, can be used successfully
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to correct Miller's class I or II recession defects. There were no statistically significant differ‐
ences between groups for any of the clinical parameters tested. [21]
In a prospective, randomized study made in 2004 by Brigido and colleagues, Graftjacket
tissue matrix, an acellular regenerative tissue matrix, has been used for wound closure. He
studied the efficacy of this tissue product in wound repair compared with conventional
treatment.  Therefore,  researchers  used  diabetic  foot  ulcers  to  evaluate  the  efficacy  of
GraftJacket tissue matrix in wound repair. Only a single administration of the tissue matrix
was required. After 1 month of treatment, preliminary results demonstrate that this novel
tissue matrix  promotes  faster  healing at  a  statistically  significant  rate  over  conventional
treatment. Because wounds in this series of patients are deep and circulation around the
wound is poor, the preliminary results suggest that this tissue matrix could be applicable
to other types of orthopedic wounds. [22]
Another multicenter, retrospective study from Winters el al. presents the use of a human
acellular dermal regenerative tissue matrix (Graftjacket regenerative tissue Matrix) as an
alternative treatment for 100 chronic, full-thickness wounds of the lower extremity in 75
diabetic patients. Wound locations included the foot (86.0%), ankle (8.0%), and lower extremity
(6.0%). Mean wound age was 20.4 weeks (1.3-191.4 weeks). University of Texas (UT) wound
classifications included 15 (15.0%) 1A, 1 (1.0%) 1B, 1 (1.0%) 1C, 2 (2.0%) 1D, 18 (18.0%) 2A, 8
(8.0%) 2B, 5 (5.0%) 2C, 3 (3.0%) 2D, 3 (3.0%) 3A, 7 (7.0%) 3B, 3 (3.0%) 3C, and 34 (34.0%) 3D.
The mean time to matrix incorporation, 100% granulation, and complete healing was 1.5 weeks
(0.43-4.4 weeks), 5.1 weeks (0.43-16.7 weeks), and 13.8 weeks (1.7-57.8 weeks), respectively.
The overall matrix success rate, as defined by full epithelialization, was 90.0%. One failed
wound subsequently healed approximately 7 weeks after matrix reapplication. The healing
rate was 91.0%, as 91 of the 100 wounds healed. No statistically significant differences were
observed between UT classifications and time to matrix incorporation, 100% granulation, and
complete healing. Absence of matrix-related complications and high rates of closure in a wide
array of diabetic wounds suggest that this matrix is a viable treatment for complex lower
extremity wounds. Lack of any statistically significant differences between UT grades and
wound outcome end points lends further support to the universal applicability of this matrix,
with successful results in both superficial diabetic wounds and in wounds penetrating to the
bone or joint. [23]
Integra bilayer wound matrix (IBWM) is a bilayer skin replacement system composed of a
dermal regeneration layer and a temporary epidermal layer. It is used to treat various types
of deep, large wounds via an inpatient procedure in an operating room. Prospective pilot study
with Integra bilayer wound matrix (IBWM) in the treatment of diabetic foot ulcers was made
by Yao and colleagues. They sought to determine ease of use and effectiveness of IBWM in an
outpatient clinical setting when treating diabetic foot ulcers. In addition, no epidermal
autografting was performed in conjunction with the IBWM after silicone release, as is common
in the inpatient setting. Eleven patients with diabetic foot ulcers were enrolled. One patient
was discontinued from the study owing to noncompliance leading to a serious adverse event.
Therefore, ten patients who received the study intervention were included in the per-protocol
population reported herein. The mean patient age was 60.6 years, with an average 11-year
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history of diabetes mellitus. Each ulcer was located on the plantar aspect of the foot. No
infection was reported during the study. Patients treated with IBWM showed progressive
wound healing over time: the greatest mean wound reduction was approximately 95% in week
12. Seven of ten patients (70%) achieved complete wound closure by week 12. No recurrent
ulcers were reported during follow-up. These results are consistent with the hypothesis that
IBWM is easy to use, safe, and effective when used on diabetic foot ulcers in an outpatient
clinical setting without the secondary procedure of autografting for closure. [24]
Purpose of retrospective comparative study from Papa et al in 2014 was to evaluate the results
of reconstruction of diabetic feet by split thickness skin graft (STSG) and by dermal substitute
Integra® covered by STSG in terms of vascularity of the reconstructed wound-bed by meas‐
urements of tissue oxygenation (TcPO2). 23 patients were included into the study (12 were
reconstructed by STSG only and 11 with Integra® and STSG three weeks later). Wound beds
reconstructed by Integra® showed on average 10 mmHg higher TcPO2. The study estimated
in an objective way, by TcPO2 value measurements, the oxygenation of the wound bed in
diabetic feet after reconstruction by STSG only and after adding dermal substitute Integra® to
the wound bed before final STSG coverage. During first month after reconstruction no
statistically significant differences were found. After 3 months TcPO2 studies revealed
statistically significant higher oxygen tissue pressure in diabetic feet covered by Integra® plus
STSG. These findings endorse in an objective way the clinical findings already reported while
using the dermal substitute. It remains to explain the role of this increase of oxygen tissue
pressure in redefine the indications for the use of dermal substitutes in reconstruction of poor
vascularized regions. [25]
3.1. Review of most recent clinical experience with acellular flowable tissue matrix
Retrospective study from Brigido et al. about an acellular flowable dermal replacement
scaffold used on lower extremity sinus tract wounds showed successful treatment potencial.
Injectable human dermal matrix has been developed for the treatment of complex diabetic
sinus tract wounds. In this retrospective series, 12 patients with deep tunneling wounds were
treated with GRAFTJACKET Xpress Scaffold and followed for 12 weeks. Complete wound
healing was achieved in 10 of 12 patients within the 12-week evaluation. The average time to
complete healing was 8.5 weeks, whereas the average time to depth healing was 7.8 weeks.
The data from the study suggest that this injectable human dermal matrix has unique prop‐
erties that allow it to facilitate healing of complex tunneling diabetic foot ulcers. The material
was easy to prepare and inject into the wound, thereby preventing the necessity of extensive
surgical exposure. The matrix supports neo-subcutaneous tissue formation and allows the
body to rapidly repair these wounds. [17]
We treated two patients with lower limb chronic wounds of different etiology: unhealed ulcer
off the stump following transmetatarsal amputation of the foot in a patient with diabetes and
a patient with foot ulcer after traumatic foot amputation. Both patients were previously treated
for two years with modern wound dressings, that were changed according to the appearance
of the bottom of the wound and the amount of exudate. Despite optimal choice of dressing
ulcers persisted. After appropriate preparation of the wound bed and removal of hypercera‐
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totic edges we applied Integra ™ Flowable Wound Matrix, which was covered with a non-
adhesive silicone dressing and polyurethane foam. After seven days, we measured the the
perimeter and the surface of the wound. The extent of the wound in the first patient was
reduced by 40% and the surface by 61%. In the second patient, the treatment was less effective,
with reduction of the perimeter by 7% and surface area by 11%. We hope to offer the new
treatment option to a larger number of patients and gather more representable data.
4. Conclusions
This review provides an outlook on some of the advanced wound healing options and
summarizes established treatment strategies of using acellular matrix and acellular flowable
wound matrix. Due to high rates of morbidity and mortality, chronic ulcers pose a global health
problem requiring substantial resources. Conventional methods of treatment are insufficient
when dealing with complex and non-healing ulcers. Advanced regenerative methods should
be considered in patients with delayed healing of ulcers, that did not reduce in size after
conventional standard 4-week treatment. The regenerative treatment should be used addito‐
nally to the conventional methods, maintaining the gold standards of appropriate debride‐
ment, infection control and moist wound healing.
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